7th Annual Liquid Biopsy for Precision Oncology Summit

The 7th Liquid Biopsy for Precision Oncology Summit returns as the largest and most comprehensive forum for all stakeholders in the field to tap into the promising opportunities that revolutionize the entire cancer patient care continuum from early translation all the way through to clinical development and commercialization.

Expect exclusive data from KOLs on the most recent developments in the utilization of liquid biopsies for early detection, prognosis and treatment. Join 200+ pioneers from the likes of Pfizer, AstraZeneca, BloodPAC, NuProbe and many more as we explore key scientific, technical, regulatory and commercial challenges associated with progressing precision oncology pipelines harnessing liquid biopsies.

URLs:
Website: https://go.evvnt.com/1420377-0?pid=10018
Tickets: https://go.evvnt.com/1420377-2?pid=10018
Brochure: https://go.evvnt.com/1420377-3?pid=10018

Prices:
Main Conference Only - Commercial Vendor: USD 3599.00,
Main Conference Only - Technical Vendors: USD 2599.00,
Main Conference Only - Drug Developer or Academic: USD 0.50

Speakers: Ahmet Zehir, Executive Director- Precision Medicine and Diagnostic Innovation, AstraZeneca, Alessandra Cesano, Chief Medical Officer, ESSA Pharma, Andrea Stevens, Director - Precision Medicine Access Strategy, Janssen, Antje Hoering, President and CEO, Cancer Research And Biostatistics, Brian Baker, Senior Director - Regulatory Affairs, Regeneron Pharmaceuticals, Carl Barrett, Vice President – Translational Science and Oncology, AstraZeneca, Dana Connors, Scientific Program Manager, Cancer Research Partnerships Foundation for the National Institutes of Health, Elizabeth Attias, Chief Strategy and Development Officer, Sermonix Pharmaceuticals, George Vasmatzis, Co-Director - Biomarker Discovery Program, Mayo Clinic, Jadwiga Bienkowska, Senior Director and Head of Computational Biology and Oncology Research, Pfizer, JD Schonhoft, Senior Principal Scientist - Translational Medicine, Repare Therapeutics, Jean-Francois Martini, Translational Oncology Lead, Pfizer, Jennifer Skenfield, Director - Clinical Operations, Oncology and Early Development, Gilead Sciences, Julien Senac, Global Director - IVD Focus Team and Strategic Account Manager, TÜV SÜD, June Lu, Senior Director - Translational Medicine, BeyondSpring Pharmaceuticals Inc., Kara Bortone, Senior Director - Precision Medicine and Enabling Technologies, Janssen, Kevin Entwistle, Director - Precision Medicine and Commercial Strategy, Janssen Global Services, LLC, Kirk Tanner, CSO and SVP Brain Tumor Investment Fund, National Brain Tumor Society, Lauren Leiman, Executive Director, BloodPAC, Marielena Mata, Senior Director and Diagnostic Lead, Pfizer, Mark Stewart, Vice President - Science Policy, Friends of Cancer Research, Nick Gallerani, Scientific Affairs, NuProbe, Nikki Martin, Senior Director - Precision Medicine Initiatives, LUNGevity, Qu Zhang, Director - Clinical Biomarkers and Immuno-Oncology, GSK, Ranjan J. Perera, Director RNA Centre, Associate Professor, Johns Hopkins School of Medicine, Robert McCormack, Independent Consultant, Sarah Paul Shagan, Principal Scientific Researcher / Biomarker Lead, Genenetch, Shrividya Iyer, Executive Director - Worldwide Real-World Evidence and Health Economics Outcomes Research, Eisai, Stacey Adam, Associate Vice President - Research Partnerships, Foundation for the National Institutes of Health, Sunanatha Setharuman, Principal Scientist, Repare Therapeutics, Yu Liang, Director - Clinical Biomarker, Compugen, Zhenhao Qi, Director - Clinical Biomarkers, Companion Diagnostics, Translational Science, Global Oncology Research and Development, Daiichi Sankyo